Is telehealth allowed to prescribe Ozempic in New York?

If you’ve been researching GLP-1 medications like Wegovy, Ozempic, or Mounjaro, you’ve probably wondered: Can I actually get these prescribed online? The short answer is yes—in most cases, you can legally access weight loss medications through telehealth in the United States. But the details matter, and they vary by state.

This guide breaks down everything you need to know about getting weight loss medication through telehealth, including federal regulations, state-specific requirements, and what to expect from the process.

Federal Regulations: The Bottom Line on Telehealth Prescribing

Here’s the most important thing to understand: GLP-1 medications like Wegovy, Ozempic, and Mounjaro are not controlled substances. This means they’re not subject to the Ryan Haight Act, which requires an in-person visit before prescribing controlled medications via telehealth.

Under federal law, healthcare providers can prescribe non-controlled medications—including all FDA-approved GLP-1 weight loss drugs—through telehealth without any mandatory in-person examination. The DEA’s COVID-era flexibilities, which remain in effect through December 31, 2025, primarily affect controlled substances like ADHD medications. For weight loss drugs, there’s no federal barrier to telehealth prescribing.

What this means for you: A licensed healthcare provider can evaluate you via video consultation and send your prescription electronically to a pharmacy, as long as they’re properly licensed in your state and you meet the medical criteria.

Free consultations available with select providers only.

Get a free consultation

And find an affordable, caring specialist.

Find a provider

Free consultations available with select providers only.

Understanding State-Specific Requirements

While federal law permits telehealth prescribing of weight loss medications, individual states have their own rules about how telemedicine must be conducted. These variations fall into several categories:

States With No In-Person Requirements

California, Connecticut, Illinois, New York, Pennsylvania, and Washington allow healthcare providers to prescribe weight loss medications entirely through telehealth. You can complete your entire evaluation, get your prescription, and maintain ongoing care without ever visiting a physical office.

In these states, providers establish a valid patient-provider relationship through live video consultations. You’ll need to provide comprehensive health information, current measurements, and commit to regular follow-ups—but all of this can happen virtually.

States Requiring Initial In-Person Exams

Arkansas, Delaware, Georgia, Mississippi, New Jersey, North Dakota, South Carolina, and Texas require patients to have at least one in-person examination before or shortly after starting telehealth treatment for weight loss.

This doesn’t mean telehealth won’t work for you in these states—it just means your treatment journey will include at least one physical appointment. Many telehealth providers partner with local clinics or labs to fulfill these requirements, making the process as convenient as possible.

New Jersey and Virginia take this a step further, requiring comprehensive initial evaluations including:

• Complete physical examination
• Laboratory testing (metabolic panel, thyroid function, etc.)
• Detailed medical history
• Personalized diet and exercise plan
• Psychological screening

States With Ongoing Visit Requirements

Florida mandates that patients receiving obesity treatment must be evaluated at least once every three months. These check-ins can typically be conducted via telehealth after an initial assessment, but the regular monitoring is legally required—not just recommended.

Virginia requires a follow-up visit within 30 days of starting weight loss medication, then regular monitoring throughout treatment.

These requirements reflect each state’s standard of care for obesity treatment and ensure patients receive proper oversight during their weight loss journey.

Who Can Prescribe Your Medication?

All licensed physicians (MDs and DOs) can prescribe GLP-1 weight loss medications via telehealth, assuming they hold an active license in your state. But what about Nurse Practitioners (NPs) and Physician Assistants (PAs)?

Independent Practice States

In states with full practice authority, NPs can evaluate patients and prescribe medications independently, without physician oversight. As of 2025, this includes:

• Arizona
• California
• Connecticut
• Delaware
• New York
• Utah
• Virginia (after 2 years of collaboration)
• Washington
• And 26 additional states plus DC

If you’re working with a telehealth platform that employs NPs in these states, you can receive the same level of care as you would from a physician.

Collaborative Practice States

States like Florida, Georgia, Illinois, Mississippi, Pennsylvania, and South Carolina require NPs and PAs to have a collaborative agreement or supervisory relationship with a physician. This doesn’t limit their ability to prescribe weight loss medications—it just means there’s a physician providing oversight of their practice.

Texas maintains particularly strict oversight, requiring formal physician agreements for NP/PA prescribing. However, since GLP-1 medications aren’t controlled substances, Texas NPs and PAs can still prescribe them under appropriate supervision.

What This Means for Patients

When you use a reputable telehealth service like Klarity Health, you might see either an MD, DO, NP, or PA depending on your state and the provider’s availability. Rest assured that all Klarity providers are appropriately licensed and credentialed to prescribe in your state. The type of provider you see doesn’t affect the quality of care—just the regulatory framework they operate under.

The Telehealth Evaluation Process: What to Expect

Getting weight loss medication through telehealth isn’t as simple as filling out a form and receiving a prescription. Legitimate telehealth providers follow rigorous clinical protocols to ensure patient safety.

Initial Consultation

Your first appointment will typically involve:

Comprehensive Medical History: You’ll discuss your weight history, previous weight loss attempts, current medications, allergies, and any relevant medical conditions. Be prepared to be honest—providers need complete information to prescribe safely.

Current Health Assessment: You’ll provide current weight, height, blood pressure (if you can measure it at home), and information about any recent lab work. Some providers may require you to visit a lab for baseline testing before prescribing.

BMI Calculation: GLP-1 medications are FDA-approved for adults with a BMI of 30 or higher, or 27 or higher with weight-related health conditions like type 2 diabetes, hypertension, or high cholesterol.

Contraindication Screening: Your provider will carefully review your history for any red flags, including:

• Personal or family history of medullary thyroid carcinoma
• Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
• Pregnancy or plans to become pregnant
• History of pancreatitis
• Severe gastrointestinal disorders
• Active gallbladder disease

Lifestyle Discussion: Reputable providers will discuss your current diet, exercise habits, sleep patterns, and stress levels. These medications work best alongside lifestyle modifications, and your provider needs to know you’re committed to comprehensive weight management.

Informed Consent

Before prescribing, your provider must obtain informed consent. This means discussing:

• How the medication works
• Common side effects (nausea, vomiting, diarrhea, constipation)
• Serious but rare risks (pancreatitis, gallstones, kidney problems)
• The need for ongoing monitoring
• What happens if you become pregnant
• Cost and insurance coverage considerations
• Alternatives to medication

Don’t rush through this. Ask questions. A provider who’s impatient with your concerns is a red flag.

Follow-Up Care

Weight loss medication isn’t a ‘set it and forget it’ treatment. Your provider will schedule regular follow-ups to:

• Monitor your weight loss progress
• Adjust your medication dosage (GLP-1s are typically titrated up gradually)
• Address any side effects
• Review lab work if needed
• Assess whether the medication is working effectively
• Reinforce lifestyle modifications

At Klarity Health, providers maintain consistent communication with patients throughout their treatment journey, ensuring you’re never navigating this alone.

Understanding the Medications: Wegovy, Ozempic, and Mounjaro

Let’s clarify what these medications are and how they differ:

Wegovy (Semaglutide 2.4mg)

FDA-approved specifically for chronic weight management in adults with obesity or overweight with at least one weight-related condition. Wegovy is administered once weekly via subcutaneous injection. Clinical trials showed an average weight loss of 15% of body weight over 68 weeks when combined with lifestyle interventions.

Telehealth Status: Fully approved for telehealth prescribing nationwide. No federal restrictions.

Typical Protocol: Start at 0.25mg weekly, gradually increase every 4 weeks up to maintenance dose of 2.4mg weekly.

Ozempic (Semaglutide 0.5-1mg)

FDA-approved for type 2 diabetes, not obesity. However, it contains the same active ingredient as Wegovy (just at lower doses) and is commonly prescribed off-label for weight loss.

Why the off-label use? During periods when Wegovy was in shortage, many providers prescribed Ozempic instead. Some insurance plans also cover Ozempic more readily than Wegovy.

Telehealth Status: Can be prescribed via telehealth, but providers must document the off-label rationale and obtain specific informed consent about using a medication outside its approved indication.

Mounjaro (Tirzepatide)

FDA-approved for type 2 diabetes. The obesity-specific version, Zepbound, was approved in late 2023 specifically for weight management. Tirzepatide works differently from semaglutide—it activates both GLP-1 and GIP receptors, potentially leading to greater weight loss.

Telehealth Status: Fully available via telehealth. Providers can prescribe Mounjaro off-label for weight loss or Zepbound on-label if appropriate.

Typical Results: Clinical trials showed an average weight loss of up to 22% of body weight at the highest dose (15mg).

Red Flags: How to Spot Illegitimate Telehealth Services

The popularity of GLP-1 medications has unfortunately attracted some questionable operators. Here’s what to watch out for:

Guaranteed Prescriptions

Red flag: Any service that promises you’ll definitely receive a prescription before you’ve completed a medical evaluation.

Why it matters: Legitimate providers screen carefully. Not everyone qualifies for these medications. If a service guarantees a prescription, they’re not practicing medicine—they’re selling drugs.

No Live Provider Interaction

Red flag: Services that only use questionnaires without any live video consultation with a licensed provider.

Why it matters: While detailed questionnaires are important, establishing a proper patient-provider relationship requires real-time interaction. Federal and state laws typically require synchronous (live) communication for prescribing.

Compounded Medications

Red flag: Services offering ‘compounded semaglutide’ or ‘custom-made’ versions of brand-name drugs.

Why it matters: In May 2025, the FDA effectively banned routine compounding of semaglutide for weight loss, declaring the shortage over. Compounded versions may not meet the same quality, safety, and efficacy standards as FDA-approved medications. Some telehealth companies, like Hims & Hers, had to discontinue their compounded semaglutide programs and lay off staff as a result.

While compounding can be legal in very limited circumstances (like for patients with specific allergies to inactive ingredients), widespread compounding of readily available drugs is prohibited.

No Follow-Up Required

Red flag: Services that prescribe without scheduling any follow-up appointments or ongoing monitoring.

Why it matters: GLP-1 medications require titration and monitoring. Legitimate providers insist on regular check-ins to assess efficacy, manage side effects, and ensure patient safety. Many states legally require periodic follow-ups for weight loss treatments.

Unclear Licensing

Red flag: Unable to verify where the provider is licensed, or the service won’t clearly state which provider will be treating you.

Why it matters: Telehealth providers must be licensed in the state where you are physically located during the consultation. If a service is vague about their providers’ credentials or locations, they may not be complying with state licensing laws.

Unrealistic Promises

Red flag: Claims of dramatic, rapid weight loss without lifestyle changes, or suggestions that the medication alone will solve your weight issues.

Why it matters: Even the most effective GLP-1 medications require commitment to dietary changes and increased physical activity. Any provider suggesting otherwise isn’t being honest about how these medications work.

Cost Considerations and Insurance Coverage

One advantage of telehealth weight loss programs is pricing transparency. Klarity Health accepts both insurance and cash pay, making treatment accessible regardless of your coverage situation.

Insurance Coverage

Coverage for GLP-1 weight loss medications varies dramatically:

• Medicare Part D generally does not cover weight loss medications (though Medicare does cover these drugs when prescribed for diabetes)
• Private insurance coverage varies by plan; some cover Wegovy but not Ozempic for weight loss, others vice versa
• Prior authorization is almost always required, which your telehealth provider can help navigate

Cash Pay Options

If insurance doesn’t cover your medication or the copays are prohibitively expensive, several options exist:

• Manufacturer savings programs: Novo Nordisk (Wegovy/Ozempic) and Eli Lilly (Mounjaro/Zepbound) offer savings cards for eligible patients
• Transparent pricing models: Klarity Health provides clear upfront pricing for both consultation fees and medication costs
• Generic alternatives: While not yet available for GLP-1s, the patent landscape is changing

Comparing Costs: Telehealth vs. Traditional Clinics

Traditional weight loss clinics often bundle services, making it hard to know what you’re paying for. Telehealth platforms typically charge:

• A consultation fee for the initial visit (often $50-200)
• Follow-up visit fees (usually lower, $30-100)
• Medication costs separate from visit fees

The transparency helps you budget and compare options. At Klarity Health, you’ll know exactly what each service costs before you commit.

State-Specific Regulatory Landscape: A Detailed Breakdown

Here’s what you need to know about telehealth weight loss prescribing in each state where we’ve verified current regulations:

Arkansas

Arkansas maintains some of the most restrictive telehealth regulations in the country. Providers must conduct an initial in-person examination before prescribing weight loss medications via telehealth. NPs require collaborative agreements with physicians. Proposals to ease these restrictions were under review in late 2025, but haven’t yet passed.

California

California leads in telehealth accessibility. No in-person exam is required, and NPs have full independent practice authority after three years of experience. The state explicitly permits telehealth prescribing for weight management.

Connecticut

Connecticut requires providers to include behavioral counseling and a diet/exercise plan as part of obesity treatment, but no in-person visit is mandated. NPs gain independence after three years of collaboration.

Delaware

Requires an initial in-person examination before telehealth prescribing. NPs achieve independent practice after two years of collaboration.

Florida

Florida requires patients to have a BMI of 30 or higher and mandates follow-up visits at least every three months. These can be conducted via telehealth after initial assessment. NPs have limited independence depending on their practice setting.

Georgia

Recently updated regulations to allow NPs and PAs to prescribe Schedule II controlled substances under physician delegation (as of July 2024). Weight loss medications require an initial in-person exam, but subsequent care can be delivered via telehealth.

Illinois

Fully permits telehealth prescribing with no special restrictions beyond standard care requirements. All prescriptions must be electronic (since 2023). NPs require written physician agreements.

Mississippi

Requires an initial in-person evaluation for weight management therapy. Legislation to grant NPs full practice authority has been introduced but not yet passed as of 2025.

New Jersey

Maintains strict requirements: comprehensive initial evaluation including physical exam, labs, and psychological screening. Follow-ups can be via telehealth. NPs require joint protocols with physicians (full practice authority legislation pending).

New York

No in-person requirements. NPs have full independence after 3,600 supervised hours. Mandatory e-prescribing applies to all medications.

North Dakota

Requires a hands-on initial evaluation, but otherwise embraces telehealth. NPs have full practice authority.

Pennsylvania

No special barriers to telehealth GLP-1 prescribing. NPs technically have independent practice authority under a 2016 law, but implementation regulations are still pending—most still work under collaboration agreements.

South Carolina

Requires initial in-person visit and periodic evaluations. NPs and PAs require physician supervision with written protocols.

Texas

One of the more restrictive states. While telehealth is broadly allowed, standard of care typically dictates an initial in-person exam for weight management. NPs cannot practice independently and require physician delegation agreements. Very strict prescriptive authority oversight.

Utah

Encourages initial in-person exam but doesn’t mandate it. NPs gained full practice authority in 2023.

Virginia

Requires initial physical exam, lab work, and personalized diet/exercise plan. Follow-up within 30 days of starting medication is mandatory. NPs achieve independence after two years.

Washington

No in-person requirements. Full NP independence. Washington’s My Health My Data Act (2023) adds additional privacy protections for telehealth, particularly relevant for sensitive weight-loss information.

The Klarity Health Advantage

At Klarity Health, we’ve designed our weight loss program to navigate this complex regulatory landscape seamlessly:

State-Licensed Providers: Every provider in our network holds active licenses in the states where they practice. You’ll never be seen by a provider who isn’t properly credentialed for your location.

Comprehensive Evaluations: We don’t cut corners. Our providers conduct thorough medical histories, discuss contraindications, and create personalized treatment plans that include lifestyle modifications alongside medication.

Flexible Scheduling: With telehealth, you’re not limited by office hours or commute times. Evening and weekend appointments make it easier to fit treatment into your life.

Transparent Pricing: We accept both insurance and cash pay, and we’re upfront about costs from the start. No surprise bills, no hidden fees.

Ongoing Support: Weight loss is a journey, not a destination. Our providers maintain regular contact throughout your treatment, adjusting your plan as needed and celebrating your successes along the way.

Compliance-First Approach: We stay current with evolving regulations in every state we serve, ensuring your treatment always meets legal and clinical standards.

What’s Next for Telehealth Weight Loss Treatment?

The regulatory landscape continues to evolve, generally in favor of expanded telehealth access:

Federal Developments: The DEA’s telehealth flexibilities for controlled substances have been extended through December 31, 2025, with signals of further extensions or permanent rules coming in 2026. Congress is considering the TREATS Act, which would permanently allow certain telehealth prescribing without in-person exams.

State Trends: More states are granting NPs full practice authority each year. As of 2025, 34 states plus DC allow independent NP practice. This trend is expected to continue, expanding access to care.

FDA Oversight: The FDA’s 2025 crackdown on compounded semaglutide demonstrates regulators’ commitment to safety while maintaining access to approved medications. This protects patients from potentially substandard products.

Insurance Coverage: As GLP-1 medications demonstrate long-term benefits and cost-effectiveness, insurance coverage is gradually expanding. More employers are adding obesity treatment to their health plans.

The bottom line: Telehealth for weight loss medications is not only legal—it’s becoming the standard of care for many patients who face barriers to traditional in-person treatment.

Frequently Asked Questions

Do I need to live in a specific state to use telehealth for weight loss medication?

You can use telehealth from any state, but the provider must be licensed in your state. Klarity Health serves multiple states and can connect you with appropriately licensed providers regardless of where you live.

How quickly can I get started?

In states without in-person requirements, you could have your first consultation within days and receive your prescription shortly after if you qualify. States requiring initial in-person exams will add some time to coordinate that visit.

What if I travel or move to a different state during treatment?

If you move permanently, you’ll need to establish care with a provider licensed in your new state. Many telehealth platforms, including Klarity, can facilitate this transition. For temporary travel, discuss with your provider—in most cases, you can continue treatment as long as your consultations occur while you’re in your home state.

Are telehealth prescriptions as safe as traditional prescriptions?

When conducted properly, telehealth prescribing meets the same safety standards as in-person care. The key is choosing a reputable provider who follows clinical protocols, screens for contraindications, and maintains ongoing monitoring.

What happens if I experience side effects?

Your telehealth provider should be accessible for questions between appointments. Most platforms offer messaging or urgent consultation options if concerning symptoms develop. Serious side effects warrant immediate medical attention—never hesitate to go to urgent care or an ER if needed.

Taking the Next Step

If you’re considering weight loss medication through telehealth, you now have the information to make an informed decision. The key is choosing a provider you trust—one that prioritizes clinical excellence, regulatory compliance, and your individual health needs.

Klarity Health makes it simple to start your weight loss journey with confidence. Our experienced providers will evaluate your unique situation, discuss whether GLP-1 medications are right for you, and create a personalized plan that includes medical treatment and lifestyle support.

Ready to take control of your weight and health? Schedule a consultation with Klarity Health today. With transparent pricing, flexible scheduling, and providers available in multiple states, we’re here to support you every step of the way—from your initial consultation through achieving and maintaining your weight loss goals.

Research Currency Statement

Verified as of: December 17, 2025

DEA Rules Status: DEA’s COVID-era telehealth flexibilities remain in effect through December 31, 2025. Non-controlled medications (like GLP-1 agonists) are not subject to the Ryan Haight Act’s in-person rule, so they can be prescribed via telehealth under federal law.

States Verified: AR, CA, CT, DE, FL, GA, IL, MS, NJ, NY, ND, PA, SC, TX, UT, VA, WA (as of December 2025)

Sources: 15 of 18 sources are from 2024–2025; older sources used only for baseline context.

Flagged for Follow-Up: Federal telehealth rules for controlled substances are temporary (set to expire 12/31/2025) – an additional extension or new rule is expected. State laws are constantly evolving; watch for changes in 2026, including pending NP practice authority bills and potential federal legislation like the TREATS Act. FDA oversight on compounded GLP-1 medications tightened in 2025.

Citations

1. DEA and HHS Extend Telemedicine Flexibilities through 2025 – Official DEA announcement (Nov 15, 2024) confirming extension of telehealth flexibilities through December 31, 2025. Available at: www.dea.gov/documents/2024/2024-11/2024-11-15/dea-and-hhs-extend-telemedicine-flexibilities-through-2025

2. COVID-era telehealth prescribing extended – Axios News (Nov 18, 2024) reporting on DEA’s three-year extension of pandemic-era telehealth rules for controlled substances. Available at: www.axios.com/2024/11/18/covid-telehealth-prescribing-extended-adderall

3. Changing Regulatory and Reimbursement Landscape for Weight Loss Drugs – Goodwin Procter legal analysis (Mar 27, 2024) detailing state-specific requirements for prescribing obesity medications in Florida, New Jersey, and Virginia. Available at: www.goodwinlaw.com/en/insights/publications/2024/03/alerts-lifesciences-hltc-changing-regulatory-reimbursement-weight-loss-drugs

4. Know Your State’s Laws Around Semaglutide – Nextech industry blog (Apr 11, 2025) providing state-by-state breakdown of semaglutide prescribing requirements and restrictions. Available at: www.nextech.com/blog/semaglutide-laws-by-state

5. Hims cuts 4% of workforce amid ban on weight loss drug copies – Reuters (May 30, 2025) reporting on FDA’s ban of compounded semaglutide products and impact on telehealth industry. Available at: www.reuters.com/business/healthcare-pharmaceuticals/hims-cut-4-workforce-amid-ban-weight-loss-drug-copies-2025-05-30

Source:

• https://www.axios.com/2024/11/18/covid-telehealth-prescribing-extended-adderall#:~:text=The%20Drug%20Enforcement%20Administration%20,year%20extension
• https://www.dea.gov/documents/2024/2024-11/2024-11-15/dea-and-hhs-extend-telemedicine-flexibilities-through-2025#:~:text=telemedicine%20flexibilities%20through%20December%2031%2C,HHS%20on%20November%2015%2C%202024
• https://www.mwe.com/insights/dea-signals-extension-of-telemedicine-flexibilities-for-controlled-substance-prescribing-for-2026/#:~:text=A%20new%20rule%20posted%20on,date%20of%20December%2031%2C%202025
• https://www.mwe.com/insights/dea-extends-telemedicine-flexibilities-for-controlled-substance-prescribing-through-december-31-2025/#:~:text=,a%20final%20set%20of%20regulations
• https://www.mwe.com/insights/dea-extends-telemedicine-flexibilities-for-controlled-substance-prescribing-through-december-31-2025/#:~:text=31%2C%202024.%20,In%20February%202023%2C%20the%20DEA
• https://www.mwe.com/insights/dea-extends-telemedicine-flexibilities-for-controlled-substance-prescribing-through-december-31-2025/#:~:text=to%20perform%20an%20in,rule%20regarding%20telemedicine%20prescribing%20of
• https://www.whitehouse.senate.gov/news/release/whitehouse-murkowski-warner-blackburn-urge-white-house-and-dea-to-extend-telehealth-flexibilities-for-substance-use-disorder-and-mental-health-treatment/#:~:text=Whitehouse%2C%20Murkowski%2C%20Warner%2C%20Blackburn%20Urge,substance%20use%20disorder%20treatment%20Washington
• https://natlawreview.com/article/arkansas-it-again-telemedicine-regulation-arkansas-undergoes-additional-change#:~:text=Arkansas%20currently%20has%20one%20of,person%20examination
• https://www.nextech.com/blog/semaglutide-laws-by-state#:~:text=Who%20can%20prescribe%20semaglutide%3F%20,
• https://natlawreview.com/article/arkansas-it-again-telemedicine-regulation-arkansas-undergoes-additional-change#:~:text=Arkansas%20currently%20has%20one%20of,encounter%20to%20establish%20a%20valid